Show simple item record

dc.contributor.authorBuchanan, R B
dc.contributor.authorBlamey, R W
dc.contributor.authorDurrant, K R
dc.contributor.authorHowell, Anthony
dc.contributor.authorPaterson, A G
dc.contributor.authorPreece, P E
dc.contributor.authorSmith, David B
dc.contributor.authorWilliams, C J
dc.contributor.authorWilson, R G
dc.date.accessioned2010-10-12T14:43:59Z
dc.date.available2010-10-12T14:43:59Z
dc.date.issued1986-09
dc.identifier.citationA randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. 1986, 4 (9):1326-30 J. Clin. Oncol.en
dc.identifier.issn0732-183X
dc.identifier.pmid3528402
dc.identifier.urihttp://hdl.handle.net/10541/112843
dc.description.abstractWe randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Metastasisen
dc.subjectOestrogen Receptorsen
dc.subject.meshAdult
dc.subject.meshBreast Neoplasms
dc.subject.meshClinical Trials as Topic
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshOligomenorrhea
dc.subject.meshOvariectomy
dc.subject.meshRandom Allocation
dc.subject.meshReceptors, Estrogen
dc.subject.meshTamoxifen
dc.titleA randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer.en
dc.typeArticleen
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractWe randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.


This item appears in the following Collection(s)

Show simple item record